147 related articles for article (PubMed ID: 30945389)
1. Combination of tanshinone IIA and doxorubicin possesses synergism and attenuation effects on doxorubicin in the treatment of breast cancer.
Li K; Liu W; Zhao Q; Wu C; Fan C; Lai H; Li S
Phytother Res; 2019 Jun; 33(6):1658-1669. PubMed ID: 30945389
[TBL] [Abstract][Full Text] [Related]
2. TanshinoneIIA enhances the chemosensitivity of breast cancer cells to doxorubicin through down-regulating the expression of MDR-related ABC transporters.
Li K; Lai H
Biomed Pharmacother; 2017 Dec; 96():371-377. PubMed ID: 29028589
[TBL] [Abstract][Full Text] [Related]
3. Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it.
Li S; Yuan S; Zhao Q; Wang B; Wang X; Li K
Biomed Pharmacother; 2018 Apr; 100():441-447. PubMed ID: 29475141
[TBL] [Abstract][Full Text] [Related]
4. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
6. Combination prostate cancer therapy: Prostate-specific membranes antigen targeted, pH-sensitive nanoparticles loaded with doxorubicin and tanshinone.
Sun G; Sun K; Sun J
Drug Deliv; 2021 Dec; 28(1):1132-1140. PubMed ID: 34121558
[TBL] [Abstract][Full Text] [Related]
7. Tanshinone IIA inhibits cardiomyocyte apoptosis and rescues cardiac function during doxorubicin-induced cardiotoxicity by activating the DAXX/MEK/ERK1/2 pathway.
Xu L; He D; Wu Y; Shen L; Wang Y; Xu Y
Phytomedicine; 2022 Dec; 107():154471. PubMed ID: 36182795
[TBL] [Abstract][Full Text] [Related]
8. Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor.
Shi J; Li J; Li J; Li R; Wu X; Gao F; Zou L; Mak WWS; Fu C; Zhang J; Leung GP
Phytomedicine; 2021 Jan; 81():153408. PubMed ID: 33234363
[TBL] [Abstract][Full Text] [Related]
9. Tanshinone II A improves the chemosensitivity of breast cancer cells to doxorubicin by inhibiting β-catenin nuclear translocation.
Li S; Wu C; Fan C; Zhang P; Yu G; Li K
J Biochem Mol Toxicol; 2021 Jan; 35(1):e22620. PubMed ID: 32886829
[TBL] [Abstract][Full Text] [Related]
10. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
Datta A; Bhasin N; Kim H; Ranjan M; Rider B; Abd Elmageed ZY; Mondal D; Agrawal KC; Abdel-Mageed AB
Cancer Lett; 2015 Jun; 362(1):25-35. PubMed ID: 25796439
[TBL] [Abstract][Full Text] [Related]
11. Quercetin Increase the Chemosensitivity of Breast Cancer Cells to Doxorubicin Via PTEN/Akt Pathway.
Li SZ; Qiao SF; Zhang JH; Li K
Anticancer Agents Med Chem; 2015; 15(9):1185-9. PubMed ID: 25612678
[TBL] [Abstract][Full Text] [Related]
12. Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system.
Wang X; Teng Z; Wang H; Wang C; Liu Y; Tang Y; Wu J; Sun J; Wang H; Wang J; Lu G
Int J Clin Exp Pathol; 2014; 7(4):1337-47. PubMed ID: 24817930
[TBL] [Abstract][Full Text] [Related]
13. Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal
He S; Wang M; Zhang Y; Luo J; Zhang Y
Contrast Media Mol Imaging; 2019; 2019():2374565. PubMed ID: 31281233
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.
Xu J; Liu D; Niu H; Zhu G; Xu Y; Ye D; Li J; Zhang Q
J Exp Clin Cancer Res; 2017 Jan; 36(1):19. PubMed ID: 28126034
[TBL] [Abstract][Full Text] [Related]
15. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
Zeng X; Zhang H; Oh A; Zhang Y; Yee D
Breast Cancer Res Treat; 2012 May; 133(1):117-26. PubMed ID: 21850397
[TBL] [Abstract][Full Text] [Related]
18. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
20. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
